A5062739537- Psoriasis: Treatment and Pathogenesis
- Inflammatory Bowel Disease
- Health Systems, Economic Evaluations, Quality of Life
- Microscopic Colitis
- Dermatology and Skin Diseases
- Rheumatoid Arthritis Research and Therapies
- Neutropenia and Cancer Infections
- Spondyloarthritis Studies and Treatments
- Blood disorders and treatments
- Antifungal resistance and susceptibility
- Blood groups and transfusion
- Autoimmune and Inflammatory Disorders Research
- Biosimilars and Bioanalytical Methods
- Complementary and Alternative Medicine Studies
- Congenital Heart Disease Studies
- Chronic Lymphocytic Leukemia Research
- Cardiovascular Function and Risk Factors
- Eosinophilic Esophagitis
- Diverticular Disease and Complications
- Pharmaceutical studies and practices
- Diagnosis and treatment of tuberculosis
- Asthma and respiratory diseases
- Lower Extremity Biomechanics and Pathologies
- Tailings Management and Properties
- Pediatric health and respiratory diseases
Navitas Systems (United States)
2021-2024
Biogen (United States)
2023
Chalmers University of Technology
2023
Brigham and Women's Hospital
2023
The Ohio State University
2012-2020
New England Research Institutes
2012-2018
New England Research (United States)
2014-2015
To compare drug survival of ixekizumab to other IL-17 inhibitors (IL-17i) and TNF (TNFi) among patients with psoriasis (PsO) in a real-world setting. Participants included adult PsO enrolled the Corrona Psoriasis Registry who initiated ixekizumab, TNFi, or IL-17i between 16 March 2016 10 August 2019 completed ≥1 follow-up visit. Multivariable adjusted hazard ratios (HR) were calculated estimate risk for discontinuation group relative drugs. Among 1604 initiations, 552 450 602 IL-17i. Mean...
BackgroundThe characteristics that predict the onset of psoriatic arthritis (PsA) among patients with psoriasis (PsO) may inform diagnosis and treatment.ObjectiveTo develop a model to 2-year risk developing PsA PsO.MethodsThis was prospective cohort study in CorEvitas Psoriasis Registry without at enrollment 24-month follow-up. Unregularized regularized logistic regression models were developed tested using descriptive variables dermatologist-identified 24 months. Model performance compared...
<b><i>Background:</i></b> Real-world studies evaluating patients with challenging-to-treat localizations of psoriasis (scalp, nail, and palmoplantar) are limited. <b><i>Objective:</i></b> To characterize versus without in areas seen routine US clinical practice. <b><i>Methods:</i></b> This retrospective observational study included all adult enrolled the Corrona Psoriasis Registry between April 2015 May 2018 who...
BACKGROUND Although the subject of many previous studies, importance white blood cell (WBC) alloimmunization in granulocyte transfusion therapy has not been settled. In this study, we report results effects WBC antibodies RING (Resolving Infection Neutropenia with Granulocytes) a randomized controlled trial comparing efficacy daily plus antimicrobials versus alone; primary outcome have published previously. STUDY DESIGN AND METHODS One hundred fourteen subjects were enrolled study. Serum...
Little is known about how psoriatic disease characteristics and treatment outcomes differ geographically in the United States. Our aim was to explore real-world, geographic variations use of biologic classes within Corrona Psoriasis Registry. Patient demographics were assessed at initiation 6 months. Logistic regressions conducted evaluate odds achieving targeted for seven States regions. We examined 737 initiations among 717 patients. IL-17 inhibitors used most frequently (45%), followed by...
Summary We compared a novel 5% testosterone (T) cream (AndroForte 5, Lawley Pharmaceuticals, Australia) with 1% T gel (Testogel, Besins Healthcare, Australia). Using an open‐label crossover design, subjects were randomized to one of two treatment sequences using either the or first in 1 : ratio. Each period was 30 days 7–14 washout between them. On Days and each blood sampled at −15, −5 min, 0, 2, 4, 6, 7, 8, 9, 10, 12 16 h post study drug administration. Sixteen men established androgen...
Abstract This study described treatment patterns in a psoriatic arthritis (PsA) patient registry for new or ongoing tumor necrosis factor inhibitor (TNFi) monotherapy, conventional synthetic disease-modifying antirheumatic drug (csDMARD) TNFi/csDMARD combination therapy. retrospective analysis included adults with PsA who enrolled the Corrona PsA/spondyloarthritis between March 21, 2013 (registry initiation), and January 31, 2017, received an approved TNFi and/or csDMARD as “existing use”...
The aim of this work is to describe real-world biologic-experienced psoriasis patients initiating ixekizumab by prior biologic therapy status and compare the effectiveness between who previously failed secukinumab those other biologics. We hypothesized that (1) clinical outcomes patient-reported would improve following a switch IXE, (2) there be no differences in responses biologics.Participants (n = 419) included adult enrolled CorEvitas Psoriasis Registry through 9/10/20 switched after...
To determine if bioabsorbable pins can be used for stabilization of comminuted articular fragments in periarticular fractures with adequate quality fixation, while eliminating the potential complications related to use traditional implants.Multicenter retrospective review.Two Level 1 trauma centers.Institutional billing records identified all cases (83) which were implanted. All charts reviewed, and fracture (80 78 patients) included.Open reduction internal fixation highly fractures, using...
There is limited real-world evidence on using ixekizumab in psoriasis patients. Therefore, we characterized patients with initiating and report 6-month changes disease patient-reported outcomes.Adult who initiated completed a follow-up visit were enrolled from the Corrona Psoriasis Registry. Disease characteristics outcomes assessed at initiation. Outcomes included mean change Area Severity Index (PASI), body surface area (BSA), Investigator Global Assessment (IGA), IGA*BSA.From baseline to...
Objective Developing and evaluating new treatment guidelines for rheumatoid arthritis (RA) based on observational data requires a quantitative understanding of patterns in current practice with biologic targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs). Methods We used from the CorEvitas RA registry to study patients starting their first b/tsDMARD therapy, defined as line between 2012 end 2021. identified unique sequences therapy changes following including first‐line...
To evaluate disease burden and patient-reported outcomes (PROs) of ulcerative colitis (UC) patients at enrollment into CorEvitas' Inflammatory Bowel Disease Registry by therapy class.Between May 3, 2017 September 2019, 773 UC registry were categorized class enrollment: on 5-aminosalicylic acids (5-ASAs) only (n = 290), biologics/Janus kinase inhibitors (JAKi) alone or in combination with 5-ASAs immunosuppressant therapies (BIO/JAKi) 315). quantify between group differences, the...
ABSTRACT To investigate how surgically created acute full‐thickness cartilage defects of similar size and location on the medial versus lateral femoral condyle influence progression spontaneous lesions in a rat model. Full‐thickness 1 mm were or condyles right leg 20 rats ( n = 10/group). Ten served as controls. Spontaneous lesion ipsilateral contralateral surfaces was examined using high‐resolution digital camera along with H&E Safranin‐O staining. Chondral scored grossly...
Real-world data are limited comparing Asian and White patients with psoriasis using biologic therapy. This study compared the 6-month effectiveness of therapy between plaque in CorEvitas Psoriasis Registry. Analyses included initiations follow-up visits from self-identified (n = 293) 2314) USA/Canada (4/2015–4/2020). Outcomes included: Area Severity Index (PASI) 75, disease activity measures [body surface area (BSA) ≤ 1, BSA 3, PASI90, PASI100, Investigator's Global Assessment (IGA) 0/1],...
Early identification, diagnosis and symptom control of psoriatic arthritis (PsA) in patients with psoriasis remain unmet medical needs.
Abstract Objectives Developing and evaluating new treatment guidelines for rheumatoid arthritis (RA) based on observational data requires a quantitative understanding of patterns in current practice with biologic targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). Methods We used from the CorEvitas RA registry to study patients starting their first b/tsDMARD therapy—defined as line therapy—between 2012 end 2021. identified unique sequences therapy changes following...
Background: Real-world data on patients newly initiating ixekizumab is limited. Our study describes the characteristics of who initiated and other biologics for psoriasis treatment in North American dermatological practices. Materials & methods: Characteristics ascertained at registry enrollment are described via means frequencies. Results: Compared with biologic initiators, initiators had: longer disease duration (17.1 vs 15.1 years); more were considered least severe by body surface...